This consensus document provides essential guidance on the safe use of cardiovascular medications in COVID-19 patients, particularly regarding antithrombotic therapy and the avoidance of dangerous drug interactions that prolong the QT interval.
Answers are grounded in this paper and cite their sources.
Guides safe statin continuation and antithrombotic/antiarrhythmic protocols in COVID-19; extends consensus to minimize QT-interaction risks.
This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs. Recommendations are provided for outpatient and inpatient antithrombotic therapy for patients with COVID-19. Issues of antithrombotic and antiviral drug interaction are discussed.
No takes yet. Share an insight, caveat, or question.
Shlyakhto et al. (2020) conducted an editorial in COVID-19. Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs was evaluated. Expert consensus guidelines recommend the continued use of statins and provide detailed protocols for antithrombotic and antiarrhythmic therapies in patients with COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: